Home > Insider Trading > Filing (0001181431-12-003409)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356857	Trius Therapeutics Inc	TSRX	Pharmaceutical Preparations (2834)	201320630

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2012-01-18	4,300	$5.56	115,700	No	4	S	Indirect	See Footnote.
Common Stock	Disposition	2012-01-19	2,600	$5.64	113,100	No	4	S	Indirect	See Footnote.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote.
No	4	S	Indirect	See Footnote.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	28	Indirect	See Footnote.

Footnotes

Shares are owned directly by Sofinnova Management VII, L.L.C. ("SV VII LLC"), the general partner of Sofinnova Venture Partners VII, L.P. ("SV VII"), and Michael Powell, a director of the issuer, James Healy and Eric Buatois, the managing members of SV VII LLC (together, the "Managing Members"), may be deemed to have shared voting and dispositive power over the shares owned by SV VII LLC.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by SV VII LLC on December 22, 2011, as amended.
Accumulated fractional shares held by SV VII.
Shares are owned directly by SV VII. SV VII LLC, the general partner of SV VII, and the Managing Members, may be deemed to have shared voting and dispositive power over the shares owned by SV VII.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.43 to $5.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.69, inclusive